Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinrong Granules
- Development stage
- Unknown
- Lead developer
- Anhui Joyfar Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xinrong Granules (心荣颗粒) is a traditional Chinese medicine (TCM) product developed by Anhui Joyfar Pharmaceutical, a subsidiary of Jingfeng Pharmaceutical. It is an oral formulation composed of extracts from *Astragalus membranaceus* (Huangqi), *Rehmannia glutinosa* (Dihuang), and *Cinnamomum cassia* (Guizhi). The drug is specifically indicated for the treatment of coronary heart disease (CHD) in patients presenting with Yang deficiency or Qi-Yin deficiency patterns. Its therapeutic mechanism involves tonifying Qi, nourishing Yin, and warming Yang to improve myocardial blood supply and overall cardiac function. Xinrong Granules has been approved for marketing in China and is utilized to manage symptoms associated with CHD and chronic heart failure.
- Brand names
- 心荣颗粒Xinrong Granules
- Other names
- Xinrong Keli
02
Targets
JUN (Transcription factor Jun)RELA (Nuclear Factor Kappa B Subunit p65)ET-1 (Endothelin-1)NOS3 (eNOS)NFKB1 (NF-κB1)JNK (Mitogen-activated protein kinase kinase kinase family)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on Xinrong Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xinrong Granules.